Login | Register

Fractionated Gemtuzumab Ozogamicin Dosing Regimen Improves Outcomes For Some Leukemia Patients

A French study published Online First in The Lancet has revealed that fractionizing the dosage of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients between the ages of 50 to 70 years with acute myeloid leukemia (AML) and significantly improves their outcomes...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *